Filter By Category
Archives
Share on -
AVACOPAN
Generic Name: AVACOPAN
ABSTRACT -
Avacopan is an oral small-molecule complement C5a receptor antagonist used where approved as adjunctive therapy for severe active ANCA-associated vasculitis. Its molecular formula is C₃₃H₃₅F₄N₃O₂. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label for the specific indication.
- Dose, duration, and monitoring requirements may differ by disease, organ function, age, and interacting medicines.
- Do not change, stop, or restart treatment without medical supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Nausea, vomiting, diarrhea, abdominal pain, or dyspepsia
- Headache, dizziness, fatigue, or rash
- Elevated liver enzymes or liver injury signals
- Hypertension or peripheral edema
- Infections, including serious infections, may occur in immunosuppressed patients
ALLERGIC REACTIONS -
Hypersensitivity to Avacopan or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avacopan should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avacopan may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Strong CYP3A4 inhibitors or inducers may alter avacopan exposure.
- Concomitant immunosuppressants can increase infection risk.
- Hepatotoxic medicines may increase the need for liver monitoring.
- Patients should report all prescription, over-the-counter, herbal, vaccine, and supplement use.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Check liver function and infection status before and during therapy as directed.
- Use caution in significant hepatic impairment or active serious infection.
- Screen and manage hepatitis B risk where clinically appropriate.
- Pregnancy and lactation decisions require specialist risk-benefit assessment.
WARNINGS –
- Serious liver injury and serious infections require prompt medical evaluation.
- Do not use as a substitute for urgent vasculitis management.
- Therapy should be supervised by clinicians experienced in ANCA-associated vasculitis.
- Keep out of reach of children.
Share on -
. Developed by